Difference between revisions of "Amrubicin (Calsed)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 12: | ||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *2002-04-11: Initial approval for the treatment of [[Small cell lung cancer|small cell]] and [[non-small cell lung cancer]]. | ||
==Also known as== | ==Also known as== | ||
| Line 25: | Line 28: | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Diseases for which it is used
Patient drug information
No information available.
History of changes in PMDA indication
- 2002-04-11: Initial approval for the treatment of small cell and non-small cell lung cancer.
Also known as
- Code name: SM-5887
- Generic names: AMR, amrubicin HCI
- Brand name: Calsed